Modification of Diet in Renal Transplantation (MDRT) (MDRT)
Nutritional Intervention for Management of Cardiovascular Risk Factors in Kidney Transplant Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jernej Pajek, MD
- Phone Number: 0038615222941
- Email: jernej.pajek@mf-uni-lj.si
Study Contact Backup
- Name: Ana Dovc, MD
- Phone Number: 0038615222941
- Email: ana.dovc@kclj.si
Study Locations
-
-
-
Ljubljana, Slovenia
- Recruiting
- University Medical Centre
-
Contact:
- Jernej Pajek, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- recipient of kidney transplant > 12 weeks after transplantation and evaluated as clinically stable
- age 18 years or more at inclusion
- estimated glomerular filtration rate (GFR) > 15 ml/min/1.73
- diagnosed dyslipidemia (LDL-cholesterol > 2.6 mmol/l (> 100 mg/dl) at inclusion or receiving lipid-lowering therapy)
- ability to participate in a lifestyle modification study.
Exclusion Criteria:
- acute illness, infection or surgical intervention requiring hospitalization in 6 weeks before inclusion, except procedures relating to arteriovenous fistula
- treatment of acute rejection or citomegalovirus infection in 6 weeks before inclusion
- chronic illness, associated with or increasing the risk of cachexia (including congestive heart failure New York Heart Association III or IV, AIDS, advanced chronic obstructive pulmonary disease, metastatic neoplastic disease or locally active neoplastic disease, chemotherapy treatment in 6 weeks before inclusion)
- clinically evident malnutrition (BMI < 18,5, reduction of body weight > 5% in 3 months before inclusion, reduction of dietary intake > 25 % from normal in 2 weeks before inclusion, serum albumin < 30 g/l (< 3 g/dl))
- nephrotic syndrome
- pregnancy
- treatment with vitamin K antagonists
- change in lipid-lowering therapy in 3 weeks before inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Plant-based diet
Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates.
Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily.
Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
|
Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling.
Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
|
|
Active Comparator: Mediterranean diet
Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates.
Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
|
Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling.
Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum low density lipoprotein (LDL)-cholesterol
Time Frame: 6 weeks and 3 months
|
Serum LDL-cholesterol concentration
|
6 weeks and 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apolipoprotein B
Time Frame: 6 weeks and 3 months
|
Apolipoprotein B serum concentration
|
6 weeks and 3 months
|
|
Reduction in insulin resistance
Time Frame: 6 weeks and 3 months
|
Change in insulin resistance, measured by Homeostatic Model Assessment (HOMA-IR)
|
6 weeks and 3 months
|
|
Serum cholesterol
Time Frame: 6 weeks and 3 months
|
Serum total cholesterol concentration
|
6 weeks and 3 months
|
|
Oxidized Low Density Lipoprotein (LDL)-cholesterol
Time Frame: 6 weeks and 3 months
|
Serum concentration of oxidized LDL-cholesterol
|
6 weeks and 3 months
|
|
Inflammatory marker high sensitive C-Reactive Protein (hs-CRP)
Time Frame: 6 weeks and 3 months
|
Serum concentration of inflammatory marker high sensitive C-reactive Protein
|
6 weeks and 3 months
|
|
Total fat tissue mass
Time Frame: 6 weeks and 3 months
|
Total body fat mass measured with bioimpedance analysis
|
6 weeks and 3 months
|
|
Lean tissue mass
Time Frame: 6 weeks and 3 months
|
Lean tissue mass measured by bioimpedance analysis
|
6 weeks and 3 months
|
|
Blood pressure
Time Frame: 6 weeks and 3 months
|
Office measured blood pressure
|
6 weeks and 3 months
|
|
Proteinuria
Time Frame: 6 weeks and 3 months
|
Spot urinary protein to creatinine-ratio of the second morning urine
|
6 weeks and 3 months
|
|
Serum potassium
Time Frame: 6 weeks and 3 months
|
Serum potassium concentration (safety outcome)
|
6 weeks and 3 months
|
|
Serum phosphate
Time Frame: 6 weeks and 3 months
|
Serum phosphate concentration
|
6 weeks and 3 months
|
|
Serum bicarbonate
Time Frame: 6 weeks and 3 months
|
Serum concentration of bicarbonate (safety outcome)
|
6 weeks and 3 months
|
|
Serum uric acid
Time Frame: 6 weeks and 3 months
|
Serum uric acid concentration (safety outcome)
|
6 weeks and 3 months
|
|
Micronutrient status of Selenium (safety outcome)
Time Frame: 6 weeks and 3 months
|
Plasma Selenium concentration
|
6 weeks and 3 months
|
|
n-3 Polyunsaturated Fatty Acid (PUFA) status
Time Frame: 6 weeks and 3 months
|
n-3 PUFA content of erythrocyte lipid fraction
|
6 weeks and 3 months
|
|
Urinary C-X-C motif chemokine 10 (CXCL10)
Time Frame: 6 weeks and 3 months
|
Urinary levels of C-X-C motif chemokine 10 (CXCL10) as an indicator of tubulointerstital and microvascular inflammation
|
6 weeks and 3 months
|
|
Gut produced uremic toxin p-cresyl sulphate
Time Frame: 6 weeks and 3 months
|
Serum level of total and free p-cresyl sulphate
|
6 weeks and 3 months
|
|
Urinary iodine concentration
Time Frame: 6 weeks and 3 months
|
Urinary level of iodine concentration in ug/L
|
6 weeks and 3 months
|
|
Plasma Zinc concentration (safety outcome)
Time Frame: 6 weeks and 3 months
|
Plasma zinc concentration
|
6 weeks and 3 months
|
|
Serum calcium concentration (safety outcome)
Time Frame: 6 weeks and 3 months
|
Serum concentration of total calcium in mmol/l
|
6 weeks and 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jernej Pajek, MD, University Medical Centre Ljubljana
Publications and helpful links
General Publications
- Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med. 2005 Sep;118(9):991-7. doi: 10.1016/j.amjmed.2005.03.039.
- Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005 Dec;5(12):2929-36. doi: 10.1111/j.1600-6143.2005.01105.x. Erratum In: Am J Transplant. 2006 Aug;6(8):1986.
- Van Breukelen GJ. ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol. 2006 Sep;59(9):920-5. doi: 10.1016/j.jclinepi.2006.02.007. Epub 2006 Jun 23. Erratum In: J Clin Epidemiol. 2006 Dec;59(12):1334.
- Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
- Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014 Jun;85(6):1303-9. doi: 10.1038/ki.2014.31. Epub 2014 Feb 19.
- Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. doi: 10.1111/j.1600-6143.2009.02834.x.
- Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, Kasiske BL; PORT Investigators. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010 Feb;10(2):338-53. doi: 10.1111/j.1600-6143.2009.02949.x.
- Authors/Task Force Members:; Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1. No abstract available.
- Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007 Dec 1;370(9602):1829-39. doi: 10.1016/S0140-6736(07)61778-4. Erratum In: Lancet. 2008 Jul 26;372(9635):292.
- Cartolano FC, Dias GD, de Freitas MCP, Figueiredo Neto AM, Damasceno NRT. Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects. J Diabetes Res. 2017;2017:1018796. doi: 10.1155/2017/1018796. Epub 2017 Aug 22.
- Claesson K, Mayer AD, Squifflet JP, Grabensee B, Eigler FW, Behrend M, Vanrenterghem Y, van Hooff J, Morales JM, Johnson RW, Buchholz B, Land W, Forsythe JL, Neumayer HH, Ericzon BG, Muhlbacher F. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc. 1998 Jun;30(4):1292-4. doi: 10.1016/s0041-1345(98)00246-2. No abstract available.
- Ferdowsian HR, Barnard ND. Effects of plant-based diets on plasma lipids. Am J Cardiol. 2009 Oct 1;104(7):947-56. doi: 10.1016/j.amjcard.2009.05.032.
- Gardner CD, Coulston A, Chatterjee L, Rigby A, Spiller G, Farquhar JW. The effect of a plant-based diet on plasma lipids in hypercholesterolemic adults: a randomized trial. Ann Intern Med. 2005 May 3;142(9):725-33. doi: 10.7326/0003-4819-142-9-200505030-00007.
- Heemann U, Abramowicz D, Spasovski G, Vanholder R; European Renal Best Practice Work Group on Kidney Transplantation. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant. 2011 Jul;26(7):2099-106. doi: 10.1093/ndt/gfr169. Epub 2011 May 9.
- Lopes TS, Luiz RR, Hoffman DJ, Ferriolli E, Pfrimer K, Moura AS, Sichieri R, Pereira RA. Misreport of energy intake assessed with food records and 24-h recalls compared with total energy expenditure estimated with DLW. Eur J Clin Nutr. 2016 Nov;70(11):1259-1264. doi: 10.1038/ejcn.2016.85. Epub 2016 Jun 8. Erratum In: Eur J Clin Nutr. 2017 May;71(5):680.
- Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000 Jan;57(1):307-13. doi: 10.1046/j.1523-1755.2000.00816.x.
- Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014 Jan 28;2014(1):CD005019. doi: 10.1002/14651858.CD005019.pub4.
- Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45. doi: 10.1161/CIRCOUTCOMES.110.959247. Epub 2011 Apr 12.
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- MDRT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.